One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

CAR T-cell therapy was first developed as a lymphoma treatment but has recently been applied to autoimmune diseases, primarily lupus, systemic sclerosis, and myositis. Up to this point, ulcerative ...

Protein tyrosine phosphatase non-receptor type 2 ( PTPN2 ) is a tyrosine phosphatase involved in T cell receptor signal ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Over the past few decades, the idea of modifying a patient’s own immune cells to recognize and destroy cancer has evolved from concept to reality. So-called “adoptive T cell therapy” has emerged as ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

Contrary to public concerns, receiving frequent COVID-19 booster vaccinations will not weaken the immune system, providing reassurance to vulnerable groups facing new variants. Study: No evidence of ...